MLH1 Deficiency Induces Cetuximab Resistance in Colon Cancer via Her‐2/PI3K/AKT Signaling
Open accessAbstract
The rapid onset of resistance to cetuximab (CTX) limits its clinical utility in colorectal cancer (CRC) patients. This study aims to understand a potential role of mismatch repair gene mutL homolog 1 (MLH1) in CTX response. Functional analysis of MLH1 in Her‐2/phosphoinositide 3‐kinases (PI3K)/PKB protein kinase (AKT)‐regulated CTX sensitivity is performed using human CRC specimens, CRC cell lines with different MLH1 expression levels, and a subcutaneous xenograft model. Overexpression, knockdown, small interfering RNA, and inhibitors are used to examine the role of MLH1 and HER‐2 downstream signaling and apoptotic targets in CTX sensitivity. Reduced MLH1 expression is correlated with unfavorable prognosis in cetuximab‐treated patients. MLH1 loss decreases CTX sensitivity through Her‐2/PI3K/AKT signaling and apoptosis resistance in culture and in xenografts, while MLH1 overexpression increases CTX sensitivity. Blocking Her‐2 signaling increases CTX sensitivity of microsatellite instability CRC in vitro and in vivo. MLH1 loss induces activation of Her‐2/PI3K/AKT signaling and leads to cetuximab resistance in colon cancer.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
hMLH1 deficiency plays a role in cetuximab resistance by increasing the expression level of ERBB2 and downstream PI3K/AKT signalling.
“It has been proven that hMLH1 deficiency plays a role in cetuximab resistance by increasing the expression level of ERBB2 and downstream PI3K/AKT signalling [130].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160 · see citing works
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863 · see citing works
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · see citing works
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622 · see citing works
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408 · see citing works
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · see citing works
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · see citing works
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P. H., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,117 · see citing works
DNA repair dysregulation from cancer driver to therapeutic target
Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051 · see citing works
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048 · see citing works
Milestones of Lynch syndrome: 1895–2015
Lynch, H. T., Snyder, C., Shaw, T. G., Heinen, C. D., & Hitchins, M. P. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3878 · Cited by 808 · see citing works
Steelman, L. S., Chappell, W. H., Abrams, S. L., Kempf, C., Long, J. M., Laidler, P. M., Mijatović, S., Maksimović‐Ivanić, D., Stivala, F., Mazzarino, M. C., et al. (2011) · Aging · doi:10.18632/aging.100296 · Cited by 689 · see citing works
The role of DNA mismatch repair in platinum drug resistance.
Fink, D. A., Nebel, S., Aebi, S. P., Zheng, H., Cenni, B., Nehmé, A., Christen, R. D., & Howell, S. B. (1996) · PubMed · Cited by 597 · see citing works
Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution
Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S., & Bardelli, A. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0462 · Cited by 513 · see citing works
Pietrantonio, F., Petrelli, F., Coinu, A., Di Bartolomeo, M., Borgonovo, K., Maggi, C., Cabiddu, M., Iacovelli, R., Bossi, I., Lonati, V., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.054 · Cited by 486 · see citing works
Giardiello, F. M., Allen, J. I., Axilbund, J. E., Boland, C. R., Burke, C. A., Burt, R. W., Church, J. M., Dominitz, J. A., Johnson, D. A., Kaltenbach, T. R., et al. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.186 · Cited by 483 · see citing works
The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer
Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., et al. (2015) · Nature · doi:10.1038/nature14969 · Cited by 479 · see citing works
Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer
Carethers, J. M., Smith, E. J., Behling, C. A., Nguyen, L., Tajima, A., Doctolero, R. T., Cabrera, B. L., Goel, A., Arnold, C., Miyai, K. N., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.12.023 · Cited by 471 · see citing works
Stintzing, S., Modest, D. P., Rossius, L., Lerch, M. M., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30269-8 · Cited by 420 · see citing works
Cetuximab: An epidermal growth factor receptor chimeric human-murine monoclonal antibody
Harding, J., & Burtness, B. A. (2005) · Drugs of today · doi:10.1358/dot.2005.41.2.882662 · Cited by 262 · see citing works
Woolston, A., Khan, K., Spain, G., Barber, L. J., Griffiths, B., Gonzalez-Exposito, R., Hornsteiner, L., Punta, M., Patil, Y., Newey, A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.013 · Cited by 254 · see citing works
Fallik, D., Borrini, F., Boige, V., Viguier, J., Jacob, S., Miquel, C., Sabourin, J., Ducreux, M. P., & Praz, F. (2003) · PubMed · Cited by 232 · see citing works
Jover, R., Zapater, P., Castells, A., Llor, X., Andreu, M. G., Cubiella, J., Piñol, V., Xicola, R. M., Bujanda, L., Reñé, J. M., et al. (2005) · Gut · doi:10.1136/gut.2005.073015 · Cited by 229 · see citing works
Ullah, A. Z. M. D., Lemoine, N. R., & Chelala, C. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks364 · Cited by 185 · see citing works
Cellular responses to EGFR inhibitors and their relevance to cancer therapy
Dutta, P. R., & Maity, A. M. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.02.006 · Cited by 181 · see citing works
Arqués, O., Chicote, I., Puig, I., Tenbaum, S. P., Argilés, G., Dienstmann, R., Fernández, N., Caratù, G., Matito, J., Silberschmidt, D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3081 · Cited by 179 · see citing works
Acquired resistance to EGFR‐targeted therapies in colorectal cancer
Emburgh, B. O. V., Bianchi, A. S., Nicolantonio, F. D., Siena, S., & Bardelli, A. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.003 · Cited by 160 · see citing works
Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges
Deng, G. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i5.787 · Cited by 157 · see citing works
The Clinical Impact of the Genomic Landscape of Mismatch Repair–Deficient Cancers
Germano, G., Amirouchene-Angelozzi, N., Rospo, G., & Bardelli, A. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0150 · Cited by 128 · see citing works
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers
Misale, S., Bozic, I., Tong, J., Peraza-Penton, A., Lallo, A., Baldi, F., Lin, K. H., Truini, M., Trusolino, L., Bertotti, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms9305 · Cited by 122 · see citing works
Role of Apoptosis in Colon Cancer Biology, Therapy, and Prevention
Zhang, L., & Yu, J. (2013) · Current Colorectal Cancer Reports · doi:10.1007/s11888-013-0188-z · Cited by 106 · see citing works
Self-citationBladder Cancer: New Insights into Its Molecular Pathology
Inamura, K. (2018) · Cancers · doi:10.3390/cancers10040100 · Cited by 100 · see citing works
Guidelines on Genetic Evaluation and Management of Lynch Syndrome
Giardiello, F. M., Allen, J. I., Axilbund, J. E., Boland, C. R., Burke, C. A., Burt, R. W., Church, J. M., Dominitz, J. A., Johnson, D. A., Kaltenbach, T. R., et al. (2014) · Diseases of the Colon & Rectum · doi:10.1097/dcr.000000000000000 · Cited by 98 · see citing works
Cohen, R., Buhard, O., Cervera, P., Hain, É., Dumont, S., Bardier–Dupas, A., Bachet, J., Gornet, J., López‐Trabada, D., Dumont, S., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.09.022 · Cited by 90 · see citing works
Aga, S. S., Nissar, S., & Fatima, K. (2014) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000019 · Cited by 76 · see citing works
Lazzari, L., Corti, G., Picco, G., Isella, C., Montone, M., Arcella, P., Durinikova, E., Zanella, E. R., Novara, L., Barbosa, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3440 · Cited by 74 · see citing works
Segelov, E., Thavaneswaran, S., Waring, P. M., Desai, J., Robledo, K. P., Gebski, V., Élez, E., Nott, L. M., Karapetis, C. S., Lunke, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.6843 · Cited by 59 · see citing works
Knockdown of Beclin‐1 impairs epithelial‐mesenchymal transition of colon cancer cells
Shen, H., Yin, L., Deng, G., Guo, C., Han, Y., Li, Y., Cai, C., Fu, Y., Liu, S., & Zeng, S. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26912 · Cited by 57 · see citing works
Self-citationLugli, A., Zlobec, I., Minoo, P., Baker, K., Tornillo, L., Terracciano, L., & Jass, J. R. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.03.002 · Cited by 43 · see citing works
Schell, M. J., Yang, M., Missiaglia, E., Delorenzi, M., Soneson, C., Yue, B., Nebozhyn, M. V., Loboda, A., Bloom, G., & Yeatman, T. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0143 · Cited by 42 · see citing works
Modjtahedi, H. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1054 · Cited by 32 · see citing works
Ma, J., Zeng, S., Zhang, Y., Deng, G., Qu, Y., Guo, C., Yin, L., Han, Y., & Shen, H. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22681 · Cited by 31 · see citing works
Self-citationGiampieri, R., Scartozzi, M., Prete, M. D., Maccaroni, E., Bittoni, A., Faloppi, L., Bianconi, M., Cecchini, L., & Cascinu, S. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.05.008 · Cited by 24 · see citing works
Xiao, X., Gong, W., WANG, S.-Z., Zhang, Z., Rui, X., WU, G.-Z., & Ren, F. (2011) · Oncology Letters · doi:10.3892/ol.2011.517 · Cited by 17 · see citing works
Ma, G., Ge, Y., Gu, D., Du, M., Chu, H., Chen, J., Zhang, Z., & Wang, M. (2016) · Gut · doi:10.1136/gutjnl-2016-311543 · Cited by 14 · see citing works
Flagged first, then by citations
1 of the 46 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- [20]D. Fink, S. Nebel, S. Aebi, H. Zheng, B. Cenni, A. Nehme, R. D. Christen, S. B. Howell, Cancer Res. 1996, 56, 4881. 8895738
- [21]D. Fallik, F. Borrini, V. Boige, J. Viguier, S. Jacob, C. Miquel, J. C. Sabourin, M. Ducreux, F. Praz, Cancer Res. 2003, 63, 5738. 14522894
- [44]K. Inamura, Cancers 2018, 10, 100.
Cited by
Sorted by citations
Yang, J., Mo, J., Dai, J., Ye, C., Cen, W., Zheng, X., Jiang, L., & Ye, L. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-04367-3 · Cited by 300 · see citing works
“demonstrated that high expression of MLH1 increase cetuximab sensitivity by blocking HER-2 signalling [34].”
BackgroundZhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246 · see citing works
Jiang, T., Wang, H., Liu, L., Hu, S., Zhang, Y., Wang, J., Liu, L., Xu, T., Fan, R., Xu, Y., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01474-9 · Cited by 130 · see citing works
Zhong, J., Ding, S., Zhang, X., Di, W., Wang, X., Zhang, H., Chen, Y., Zhang, Y., & Hu, Y. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2802037 · Cited by 54 · see citing works
Self-citationComprehensive review of the resistance mechanisms of colorectal cancer classified by therapy type
Oh, J. M., Kim, S. W., Tsung, C., Kent, E. W., Jain, A., Ruff, S. M., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1571731 · Cited by 49 · see citing works
The Use of ctDNA in the Diagnosis and Monitoring of Hepatocellular Carcinoma—Literature Review
Kopystecka, A., Patryn, R. K., Leśniewska, M., Budzyńska, J., & Kozioł, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119342 · Cited by 36 · see citing works
Contursi, A., Fullone, R., Szklanna, P. B., Marcone, S., Lanuti, P., Taus, F., Meneguzzi, A., Turri, G., Dovizio, M., Bruno, A., et al. (2023) · Cancers · doi:10.3390/cancers15020350 · Cited by 33 · see citing works
Albadari, N. G., Xie, Y., & Li, W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1340401 · Cited by 30 · see citing works
Zhang, H., Yi, J., Huang, H., Park, S., Kwon, W., Kim, E.-K., Jang, S., Kim, S., Choi, S., Yoon, D., et al. (2021) · Journal of Ginseng Research · doi:10.1016/j.jgr.2021.07.004 · Cited by 27 · see citing works
MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer
Zhang, Y., Liang, S., Xiao, B., Hu, J., Pang, Y., Liu, Y., Yang, J., Ao, J., Wei, L., & Luo, X. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04709-9 · Cited by 22 · see citing works
Ren, S.-N., Zhang, Z.-Y., Guo, R.-J., Wang, D., Chen, F., Chen, X., & Fang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i13.1911 · Cited by 19 · see citing works
Multi-Omics Prognostic Signatures Based on Lipid Metabolism for Colorectal Cancer
Sun, Y., Liu, B., Chen, Y., Xing, Y., & Zhang, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.811957 · Cited by 16 · see citing works
Self-citationHsa_Circ_0066351 Acts as a Prognostic and Immunotherapeutic Biomarker in Colorectal Cancer
Gao, Y., Zhou, Y., Le, W., Feng, Z., Chen, Y., Liu, P., Peng, Y., Huang, Q., Gao, L., Liu, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927811 · Cited by 16 · see citing works
Self-citationWei, Z., Wang, Z., Chai, Q., Li, Z., Zhang, M., Zhang, Y., Zhang, L., Tang, Q., Zhu, H., & Sui, H. X. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11785 · Cited by 16 · see citing works
Chen, W., Dai, G., Qian, Y., Lian, W., He, X., Liu, H., Gao, Y., Tang, X., & Dong, B. (2021) · Oncology Reports · doi:10.3892/or.2021.8222 · Cited by 16 · see citing works
Cai, J., Sun, H., Chen, L., Xie, M., Zhuang, J., Gao, L., & Wei, X. X. (2021) · Future Oncology · doi:10.2217/fon-2020-0992 · Cited by 12 · see citing works
Fang, Z.-X., Li, C., Chen, W.-J., Wu, H.-T., & Liu, J. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i9.1675 · Cited by 10 · see citing works
Zhang, X., Huang, H.-Y., Sun, S., Li, D., Sun, L., Li, Q., Chen, R., Lai, X., Zhang, Z., Zheng, X., et al. (2022) · Molecules · doi:10.3390/molecules27238272 · Cited by 10 · see citing works
Hu, T., Yang, J., Yan, Y., Chen, Y., Xue, H.-B., Xiang, Y., & Ye, L. (2020) · Bioscience Reports · doi:10.1042/bsr20201125 · Cited by 10 · see citing works
Self-citationThe Prognostic Significance of RIMKLB and Related Immune Infiltrates in Colorectal Cancers
Cao, Y., Deng, S., Yan, L., Gu, J., Mao, F., Xue, Y., Qin, L., Jiang, Z., Cai, W., Zheng, C., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.818994 · Cited by 9 · see citing works
Galectin‑3 blockade suppresses the growth of cetuximab‑resistant human oral squamous cell carcinoma
Yin, P., Cui, S., Liao, X., & Yao, X. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12325 · Cited by 9 · see citing works
RetractedWang, C., Yang, M., Gu, X., & Gu, Y. (2021) · Bioengineered · doi:10.1080/21655979.2021.1974655 · Cited by 8 · see citing works
Li, X., Dong, H., Zheng, Y., Ding, S., Li, Y., Li, H., Huang, H., Zhong, C., Xie, T., & Xu, Y. (2023) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2023.101939 · Cited by 7 · see citing works
Self-citationLiu, S., Peng, X., Wu, X., Bu, F., Yu, Z., Zhu, J., Luo, C. H., Zhang, W., Liu, J., & Huang, J. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02508-2 · Cited by 5 · see citing works
Self-citationWei, W., Li, J., Huang, J., Jiang, Q., Lin, C., Hu, R., Wei, J., Li, Q., Xu, G., & Chang, Z. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13459 · Cited by 5 · see citing works
Zhou, L., Le, K., Chen, Q., & Wang, H. (2024) · BMC Oral Health · doi:10.1186/s12903-024-04459-4 · Cited by 4 · see citing works
miR-196b strictly regulates and reliably predicts the response to cetuximab in colorectal cancer
Chen, S., Tan, Z.-L., Lin, Y., Pang, F., Wu, X., Li, X., Cui, Y., Man, W., Li, Y., Li, Y., et al. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-025-00740-8 · Cited by 3 · see citing works
Self-citationTensor Robust PCA Based on Transformed Tensor Singular Value Decomposition for Cancer Genomic Data
Zhang, S., Zhang, Y., Liu, J., Wang, J., Shang, J., & Ge, D. (2022) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm55620.2022.9994952 · Cited by 3 · see citing works
Her-2 nanobody modified cisplatin nanoparticles for precise chemotherapy of colon cancer
Liang, W., Zhang, Y., Li, J., Ji, C., & Jiang, X. (2025) · Journal of Microencapsulation · doi:10.1080/02652048.2025.2467060 · Cited by 2 · see citing works
Jiang, H., Su, W.-C., Wang, H., Luo, C., Wang, Y., Zhang, L., Luo, L., Lu, Z., Shen, D., & Su, G. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24807 · Cited by 1 · see citing works
Zhang, X., Huang, H.-Y., Sun, S., Li, D., Sun, L., Li, Q., Chen, R.-H., Lai, X., Zhang, Z., Zheng, X., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2160631/v1 · Cited by 1 · see citing works
Zhang, S., Wei, Y., Liu, T., Sun, C., Ge, X., Ni, Y., Tang, X., Roy, M., Chang, T., & Kang, X. (2025) · Biological Procedures Online · doi:10.1186/s12575-025-00303-3
Zhou, L., Le, K., Chen, Q., & Wang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26507227
- Authors
- Han, Y., Peng, Y., Fu, Y., Cai, C., Guo, C., Liu, S., Li, Y., Chen, Y., Shen, E., Long, K., Wang, X., Yu, J., Shen, H., & Zeng, S.
- Affiliations
- Central South University (CN)
- McMaster University (CA)
- University of Pittsburgh (US)
- Corresponding author
- Yu, Jian
- Shen, Hong
- Zeng, Shan
- ORCID
- Venue
- Advanced Science
- Publisher
- Wiley
- Published
- 2020-05-26
- Volume
- 7
- Issue
- 13
- Pages
- 2000112-2000112
- ISSN
- 2198-3844 (ISSN-L)
- PMC
- PMC7341094
- OpenAlex
- W3028710404
- Cited by
- 34
- References
- 46
- Citations by year
- 2025: 5 · 2024: 4 · 2023: 6 · 2022: 9 · 2021: 8 · 2020: 2
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Advanced Science (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81070362, 81172470, 81372629, 81772627, 81874073, 81974384)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- MLH1, cetuximab resistance, colon cancer, colorectal cancer, HER2, PI3K/Akt signaling, mismatch repair deficiency, microsatellite instability, apoptosis resistance, EGFR inhibitors, prognosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
